By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem AG celebrates 50th Birthday
Bubendorf, Switzerland: – Bachem AG has been celebrating the 50th Anniversary of its 1971 founding by Dr. Peter Grogg in Liestal, in the canton of Basel-Country in Switzerland.
Over the course of the subsequent half century Bachem has become a global leader in the development and production of peptides, oligonucleotides and important ingredients for research and a range of vital medicines that treat cancer, diabetes and other diseases.
From Liestal to Bubendorf
Six years after the company was founded, Peter Grogg and his eight colleagues moved a few kilometers south to a small laboratory at Bubendorf, which is where the company has remained to this day, producing a portfolio of advanced peptides and research materials on what is now a two hectare site boasting some of the world’s most advanced pharmaceutical and biotech production facilities, making it an important supplier to the global life sciences industry.
Bachem has also grown into a company that employs more than 1,500 people at six locations worldwide. During 2020, revenues topped CHF 400 million (365m Euros) for the first time while a further 272 new employees joined the company. Bachem’s further growth plans include an investment of more than CHF 400 million in company expansion over the next five years.
The anniversary celebrations for employees, originally planned on site, was held as a virtual event due to the COVID-19 pandemic.
Company founder and Honorary Chairman, Dr. Peter Grogg, commented: “Today we celebrate 50 exciting and successful years of company history. Bachem’s success continues to be rooted in the skills and dedication of its employees. I am certain that Bachem has many more exciting and successful years ahead of it.”
Dr. Kuno Sommer, Chairman of the Board of Directors, added: “Bachem’s exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg’s values and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision.”
CEO Thomas Meier said: “Today’s anniversary is a commitment to the next 50 years. We intend and are able to continue to grow independently and profitably. That is why we are continuing to invest in the future of all our sites. In doing so, we will build on our strengths: our company culture and our commitment to high quality, innovation and customer focus.”
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia.
The company is listed on the SIX Swiss Exchange. For further information, visit the Bachem website.